MXPA04007183A - Composicion farmaceutica para el control de la glucosa en sangre de pacientes con diabetes tipo 2. - Google Patents
Composicion farmaceutica para el control de la glucosa en sangre de pacientes con diabetes tipo 2.Info
- Publication number
- MXPA04007183A MXPA04007183A MXPA04007183A MXPA04007183A MXPA04007183A MX PA04007183 A MXPA04007183 A MX PA04007183A MX PA04007183 A MXPA04007183 A MX PA04007183A MX PA04007183 A MXPA04007183 A MX PA04007183A MX PA04007183 A MXPA04007183 A MX PA04007183A
- Authority
- MX
- Mexico
- Prior art keywords
- diabetes
- patients
- blood glucose
- type
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Abstract
Se aportan composiciones farmaceuticas de las sustancias activas Glimepirida y Metformina o sus sales como clorhidrato, succinato fumarato, etc. para el control de la glucosa en sangre de pacientes con diabetes tipo 2. Para probar la eficacia de la combinacion se realizaron estudios clinicos que probaron que existe un efecto no solo aditivo de los dos farmacos sino sinergetico, en comparacion con la monoterapia empleando solo algunos de los farmacos de la combinacion. En consecuencia se propone el uso de la combinacion como una terapia eficaz y segura para el control de glucosa en sangre de pacientes con diabetes tipo 2 empleando diversas proporciones de las sustancias activas en las combinaciones, para adecuarse a las diferentes necesidades de los pacientes.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA04007183A MXPA04007183A (es) | 2002-01-25 | 2002-01-25 | Composicion farmaceutica para el control de la glucosa en sangre de pacientes con diabetes tipo 2. |
BRPI0502691-1A BRPI0502691A (pt) | 2002-01-25 | 2005-07-08 | composição farmacêutica para o controle da glicose no sangue de pacientes com diabetes tipo 2 |
ARP050103077A AR050684A1 (es) | 2004-07-26 | 2005-07-25 | Composicion farmaceutica que comprende metformina o sus sales aceptables para uso farmaceutico con glimepirida y uso de metformina o sus sales aceptables para uso farmaceutico y glimepirida para la manufactura de un medicamento |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA04007183A MXPA04007183A (es) | 2002-01-25 | 2002-01-25 | Composicion farmaceutica para el control de la glucosa en sangre de pacientes con diabetes tipo 2. |
PCT/MX2002/000003 WO2003061643A1 (es) | 2002-01-25 | 2002-01-25 | Composicion farmaceutica para el control de la glucosa en sangre de pacientes con diabetes tipo 2 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA04007183A true MXPA04007183A (es) | 2006-03-06 |
Family
ID=27607097
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA04007183A MXPA04007183A (es) | 2002-01-25 | 2002-01-25 | Composicion farmaceutica para el control de la glucosa en sangre de pacientes con diabetes tipo 2. |
Country Status (11)
Country | Link |
---|---|
US (2) | US9045438B2 (es) |
EP (1) | EP1482919B1 (es) |
AT (1) | ATE361065T1 (es) |
BR (1) | BRPI0502691A (es) |
CY (1) | CY1106771T1 (es) |
DE (1) | DE60219963T2 (es) |
DK (1) | DK1482919T3 (es) |
ES (1) | ES2284829T3 (es) |
MX (1) | MXPA04007183A (es) |
PT (1) | PT1482919E (es) |
WO (1) | WO2003061643A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MXPA04007183A (es) | 2002-01-25 | 2006-03-06 | Silanes Sa De Cv Lab | Composicion farmaceutica para el control de la glucosa en sangre de pacientes con diabetes tipo 2. |
AU2002356419A1 (en) | 2002-06-17 | 2003-12-31 | Themis Laboratories Private Limited | Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them |
MXPA05009633A (es) * | 2005-09-08 | 2007-03-07 | Silanes Sa De Cv Lab | Composicion farmaceutica estable de glimepirida de liberacion inmediata y metformina de liberacion prolongada. |
FR2896157B1 (fr) * | 2006-01-13 | 2008-09-12 | Merck Sante Soc Par Actions Si | Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline. |
US20120095059A1 (en) * | 2010-04-13 | 2012-04-19 | Jorge Luis Rosado | Compositions and Methods for Treating Type II Diabetes and Related Disorders |
MX339374B (es) * | 2011-04-29 | 2016-05-13 | Inst De Investigación En Química Aplic S A De C V | Cocristales ionicos con base en metformina. |
US9171343B1 (en) | 2012-09-11 | 2015-10-27 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
US9897565B1 (en) | 2012-09-11 | 2018-02-20 | Aseko, Inc. | System and method for optimizing insulin dosages for diabetic subjects |
EP2712628B1 (en) * | 2012-09-28 | 2016-08-10 | Shanta Banerjee | Composition for use as a medicine or dietetic food, in particular in the prevention and/or treatment of Diabetes and diabetes associated diseases |
US9898585B2 (en) | 2014-01-31 | 2018-02-20 | Aseko, Inc. | Method and system for insulin management |
US9486580B2 (en) | 2014-01-31 | 2016-11-08 | Aseko, Inc. | Insulin management |
US11081226B2 (en) | 2014-10-27 | 2021-08-03 | Aseko, Inc. | Method and controller for administering recommended insulin dosages to a patient |
EP3050023B1 (en) | 2014-10-27 | 2021-08-25 | Aseko, Inc. | Subcutaneous outpatient management |
WO2016168388A2 (en) | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
AU2016308953B2 (en) | 2015-08-20 | 2020-09-10 | Aseko, Inc. | Diabetes management therapy advisor |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3072527A (en) | 1959-07-01 | 1963-01-08 | Horner Frank W Ltd | Use of tolbutamide in the treatment of acne |
JP3465247B2 (ja) | 1992-12-28 | 2003-11-10 | アベンティス ファーマ株式会社 | 動脈硬化症の予防および治療剤 |
DE4432757A1 (de) * | 1994-09-14 | 1996-03-21 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung |
US6348469B1 (en) | 1995-04-14 | 2002-02-19 | Pharma Pass Llc | Solid compositions containing glipizide and polyethylene oxide |
IT1276130B1 (it) | 1995-11-14 | 1997-10-27 | Gentili Ist Spa | Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo |
US6011049A (en) * | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
DE69822505T2 (de) * | 1997-12-08 | 2005-01-20 | Bristol-Myers Squibb Co. | Neue metformin-salze und verfahren |
PT974356E (pt) | 1998-07-15 | 2004-02-27 | Merck Sante Sas | Comprimidos compreendendo uma combinacao de metformina e de glibenclamida |
DE19860698A1 (de) * | 1998-12-30 | 2000-07-06 | Hexal Ag | Neue pharmazeutische Zusammensetzung |
US6559188B1 (en) * | 1999-09-17 | 2003-05-06 | Novartis Ag | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
US6586438B2 (en) * | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
US6499984B1 (en) * | 2000-05-22 | 2002-12-31 | Warner-Lambert Company | Continuous production of pharmaceutical granulation |
WO2002011716A2 (en) * | 2000-08-07 | 2002-02-14 | Ranbaxy Signature Llc | Liquid formulation of metformin |
FR2825023B1 (fr) | 2001-05-23 | 2005-04-15 | Flamel Tech Sa | Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif |
MXPA04007183A (es) | 2002-01-25 | 2006-03-06 | Silanes Sa De Cv Lab | Composicion farmaceutica para el control de la glucosa en sangre de pacientes con diabetes tipo 2. |
US6682759B2 (en) | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
US20030187074A1 (en) | 2002-03-04 | 2003-10-02 | Javed Hussain | Oral compositions for treatment of diabetes |
EP1562607A1 (en) | 2002-11-15 | 2005-08-17 | Ranbaxy Laboratories, Ltd. | Pharmaceutical dosage forms of biguanide-sulfonylurea combinations |
MXPA05009633A (es) | 2005-09-08 | 2007-03-07 | Silanes Sa De Cv Lab | Composicion farmaceutica estable de glimepirida de liberacion inmediata y metformina de liberacion prolongada. |
-
2002
- 2002-01-25 MX MXPA04007183A patent/MXPA04007183A/es active IP Right Grant
- 2002-01-25 ES ES02710518T patent/ES2284829T3/es not_active Expired - Lifetime
- 2002-01-25 PT PT02710518T patent/PT1482919E/pt unknown
- 2002-01-25 DK DK02710518T patent/DK1482919T3/da active
- 2002-01-25 DE DE60219963T patent/DE60219963T2/de not_active Expired - Lifetime
- 2002-01-25 EP EP02710518A patent/EP1482919B1/en not_active Expired - Lifetime
- 2002-01-25 WO PCT/MX2002/000003 patent/WO2003061643A1/es active IP Right Grant
- 2002-01-25 AT AT02710518T patent/ATE361065T1/de active
- 2002-01-25 US US10/502,403 patent/US9045438B2/en not_active Expired - Fee Related
-
2005
- 2005-07-08 BR BRPI0502691-1A patent/BRPI0502691A/pt not_active Application Discontinuation
-
2007
- 2007-07-30 CY CY20071101008T patent/CY1106771T1/el unknown
-
2015
- 2015-06-01 US US14/727,396 patent/US20160051511A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
ATE361065T1 (de) | 2007-05-15 |
DE60219963T2 (de) | 2008-02-07 |
US20050239887A1 (en) | 2005-10-27 |
BRPI0502691A (pt) | 2006-03-07 |
EP1482919B1 (en) | 2007-05-02 |
PT1482919E (pt) | 2007-07-25 |
ES2284829T3 (es) | 2007-11-16 |
DK1482919T3 (da) | 2007-07-30 |
US9045438B2 (en) | 2015-06-02 |
EP1482919A1 (en) | 2004-12-08 |
CY1106771T1 (el) | 2012-05-23 |
DE60219963D1 (de) | 2007-06-14 |
WO2003061643A1 (es) | 2003-07-31 |
US20160051511A1 (en) | 2016-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY26425A1 (es) | Formulación y método antidiabético | |
MXPA04007183A (es) | Composicion farmaceutica para el control de la glucosa en sangre de pacientes con diabetes tipo 2. | |
BR9907866A (pt) | Composição farmacêutica compreendendo uma combinação de metformina e fibrato, e seu uso para a preparação de medicinas destinadas a reduzir a hiperglicemia | |
DE60236541D1 (de) | Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1 | |
BR0307291A (pt) | Composto; processo para a preparação de um composto; composição farmacêutica; uso de um composto; método para o tratamento e profilaxia de distúrbios diversos e de obesidade em um humano | |
BRPI0519181A2 (pt) | composto ou um sal farmaceuticamente aceitÁvel do mesmo, processo para preparar o mesmo, composiÇço farmacÊutica, uso de um composto ou um sal farmaceuticamente aceitÁvel do mesmo, e, mÉtodos para produzir um efeito inibitàrio de b-raf em um animal de sangue quente, para produzir um efeito anti-cÂncer em um animal de sangue quente e para tratar uma doenÇa em um animal de sangue quente | |
MXPA04004837A (es) | Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1. | |
MXPA04004842A (es) | Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1. | |
JP2019517542A5 (es) | ||
TW200633978A (en) | 2,3,4,9-tetrahydro-1H-carbazole derivatives as crth2 receptor antagonists | |
EP2392322A3 (en) | Dosing regimes for trans-clomiphene | |
WO2007064448A3 (en) | Cancer treatment using fts and 2-deoxyglucose | |
SE9901573D0 (sv) | New compounds | |
RS44204A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
EP1393738A4 (en) | MEDICINE AGAINST DIABETES | |
BRPI0410761A (pt) | uso de leucina, e, composição para administração entérica a pacientes | |
TNSN06072A1 (en) | Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep | |
RS44304A (en) | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | |
LT2006024A (en) | Tetrapeptide regulating blood glucose level in diabetes mellitus | |
BRPI0410374A (pt) | composição farmacêutica que compreende valsartano | |
IL163091A (en) | Medical product and pharmaceutical composition comprising as active ingredients a thrombolytic agent and levosimendan or a pharmaceutically acceptable salt thereof and the use of same in the manufacture of medicament for reducing mortality of patients with acute myocardial infarction | |
TR200201654T2 (tr) | Benzamidin türevleri. | |
RU2004103531A (ru) | Фармацевтическая композиция для перорального применения, содержащая одновременно метформин и гликлазид | |
KR20220085094A (ko) | 알레르기성 결막염을 동반한 만성 비염을 치료하는 약제학적 복합제제 | |
TW200515912A (en) | Use of oxcarbazepine for the treatment of diabetic neuropathic pain and the improvement of sleep |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |